ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Some of the observed relapses following discontinuation of treatment may be a result of CML LSC activity, which would reconstitute BCR::ABL1 transcript levels in patients previously observed to be in DMR or having a sustained undetectable molecular response whilst maintaining a low mutational burden [6, 7, 9, 10].